Schwab Charles Investment Management Inc. boosted its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 5.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,402,341 shares of the biopharmaceutical company’s stock after buying an additional 270,982 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.33% of Bristol-Myers Squibb worth $301,019,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Tradewinds Capital Management LLC raised its position in Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares during the last quarter. Welch Investments LLC raised its position in Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the last quarter. Blue Chip Partners Inc. raised its position in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. American National Bank raised its position in Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its position in Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the last quarter. 68.84% of the stock is owned by institutional investors.

A number of equities analysts have issued reports on BMY shares. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 26th. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Cowen and Company set a $65.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, July 10th. Jefferies Group LLC reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. Finally, Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price target for the company in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $63.79.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/21/schwab-charles-investment-management-inc-acquires-270982-shares-of-bristol-myers-squibb-company-bmy.html.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 64.42 on Friday. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10. The firm has a market cap of $105.64 billion, a PE ratio of 23.53 and a beta of 1.19. The company has a 50-day moving average of $63.37 and a 200-day moving average of $57.29.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 earnings per share. Analysts predict that Bristol-Myers Squibb Company will post $2.99 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.42%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.